Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
Jorge Gutiérrez‐Cuevas, Arturo Santos, Juan Armendáriz‐Borunda
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11629-11629
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 82
Research progress of proanthocyanidins and anthocyanidins
Yang Zhao, Chengqing Jiang, Jiaying Lu, et al.
Phytotherapy Research (2023) Vol. 37, Iss. 6, pp. 2552-2577
Closed Access | Times Cited: 50
Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?
Mariana M. Ramírez-Mejía, Carlos Jiménez-Gutiérrez, Mohammed Eslam, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 168-178
Closed Access | Times Cited: 50
MAFLD predicts cardiovascular disease risk better than MASLD
Ziyan Pan, Gamal Shiha, Gamal Esmat, et al.
Liver International (2024) Vol. 44, Iss. 7, pp. 1567-1574
Closed Access | Times Cited: 27
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Dietary Inflammatory Index and Its Association with the Prevalence of Coronary Heart Disease among 45,306 US Adults
Li‐Da Wu, Yi Shi, Chaohua Kong, et al.
Nutrients (2022) Vol. 14, Iss. 21, pp. 4553-4553
Open Access | Times Cited: 41
The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors
Jorge Gutiérrez‐Cuevas, Marina Galicia‐Moreno, Hugo Christian Monroy-Ramírez, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 235-235
Open Access | Times Cited: 40
Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies
Jorge Gutiérrez‐Cuevas, Silvia Lucano‐Landeros, Daniel López-Cifuentes, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 23-23
Open Access | Times Cited: 38
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Haixiang Zheng, Leonardo A. Sechi, Eliano Pio Navarese, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 10
Heterogeneously elevated branched-chain/aromatic amino acids among new-onset type-2 diabetes mellitus patients are potentially skewed diabetes predictors
Min Wang, Yang Ou, Xiang-Lian Yuan, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 1, pp. 53-71
Open Access | Times Cited: 8
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease
Marenao Tanaka, Kazuma Mori, Satoko Takahashi, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 3, pp. 700-711
Closed Access | Times Cited: 35
Atherosclerosis and multi-organ-associated pathologies
W. Coles Keeter, Shelby Ma, Natalie Stahr, et al.
Seminars in Immunopathology (2022) Vol. 44, Iss. 3, pp. 363-374
Open Access | Times Cited: 32
Metabolic dysfunction: The silenced connection with fatty liver disease
Mariana M. Ramírez-Mejía, Xingshun Qi, Ludovico Abenavoli, et al.
Annals of Hepatology (2023) Vol. 28, Iss. 6, pp. 101138-101138
Open Access | Times Cited: 17
Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses
Kazuma Mori, Marenao Tanaka, Itaru Hosaka, et al.
Hypertension Research (2023) Vol. 46, Iss. 5, pp. 1110-1121
Closed Access | Times Cited: 15
Relationship Between Plasma Aldosterone Concentrations and Non-Alcoholic Fatty Liver Disease Diagnosis in Patients with Hypertension: A Retrospective Cohort Study
Junli Hu, Xintian Cai, Qing Zhu, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 1625-1636
Open Access | Times Cited: 15
Deciphering metabolic dysfunction‐associated steatotic liver disease: insights from predictive modeling and clustering analysis
Kazuma Mori, Yukinori Akiyama, Marenao Tanaka, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 7, pp. 1382-1393
Open Access | Times Cited: 6
Exploring the Link between Oxidative Stress, Selenium Levels, and Obesity in Youth
Teofana Bizerea, Laura Pitulice, Otilia Bizerea-Spiridon, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7276-7276
Open Access | Times Cited: 6
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation
Ludovico Abenavoli, Maria Luisa Gambardella, Giuseppe Guido Maria Scarlata, et al.
Medicina (2024) Vol. 60, Iss. 4, pp. 563-563
Open Access | Times Cited: 5
CXCL9, IL2RB, and SPP1, potential diagnostic biomarkers in the co-morbidity pattern of atherosclerosis and non-alcoholic steatohepatitis
Xize Wu, Changbin Yuan, Jiaxiang Pan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5
Medicinal Plant Extracts against Cardiometabolic Risk Factors Associated with Obesity: Molecular Mechanisms and Therapeutic Targets
Jorge Gutiérrez‐Cuevas, Daniel López-Cifuentes, Ana Sandoval-Rodríguez, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 967-967
Open Access | Times Cited: 5
Associating plasma aldosterone concentration with the prevalence of MAFLD in hypertensive patients: insights from a large-scale cross-sectional study
Shen Di, Xintian Cai, Junli Hu, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 5
An Overview of the Current Scientific Evidence on the Biological Properties of Abelmoschus esculentus (L.) Moench (Okra)
Carsten Tsun‐Ka Kwok, Yam-Fung Ng, Henry Chan, et al.
Foods (2025) Vol. 14, Iss. 2, pp. 177-177
Open Access
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access
Novel bioactive peptides alleviate Western diet-induced MAFLD in C57BL/6J mice by inhibiting NLRP3 inflammasome activation and pyroptosis via TLR4/NF-κB and Keap1/Nrf2/HO-1 signaling pathways
Vipul Wayal, Shulhn-Der Wang, Chang‐Chi Hsieh
International Immunopharmacology (2025) Vol. 148, pp. 114177-114177
Open Access
Adolescent Obesity and Charlson Comorbidity Index in Young Adults
Yulia Treister‐Goltzman, Idan Menashe, Dan Nemet
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 873-873
Open Access
Page 1 - Next Page

Scroll to top